PPP1R1B
Reaktivität: Human
WB, IHC, ELISA, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Recommended Dilution: WB: 1:1000 Quality Control: Western blots performed on each lot.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
100 μL in 10 mM HEPES ( pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.
Lagerung
-20 °C
Gomez, Midde, Mactutus, Booze, Zhu: "Environmental enrichment alters nicotine-mediated locomotor sensitization and phosphorylation of DARPP-32 and CREB in rat prefrontal cortex." in: PLoS ONE, Vol. 7, Issue 8, pp. e44149, (2013) (PubMed).
Cantrup, Sathanantham, Rushlow, Rajakumar: "Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens." in: Neuroscience, Vol. 222, pp. 124-35, (2012) (PubMed).
Napolitano, Bonito-Oliva, Federici, Carta, Errico, Magara, Martella, Nistica: "Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 30, Issue 33, pp. 11043-56, (2010) (PubMed).
DARPP-32 is a dopamine (DA) and cAMP-regulated ~32k phosphoprotein that is associated with dopaminoceptive neurons (Fienberg et al., 1998). The protein inhibits protein phosphatase I when it is phosphorylated on Thr34. In contrast, when DARPP-32 is phosphorylated on Thr75 the protein acts as an inhibitor of PKA (Bibb et al., 1999). Phosphorylation of DARPP-32 is thought to play a critical role in the regulation of dopaminergic neurotransmission. In addition, the activity of DARPP-32 is also thought to play important roles in the actions of alcohol, caffeine and Prozac (Maldve et al., 2002, Lindskog et al., 2002, Svenningsson et al., 2002). Anti-Phospho Thr75 DARPP-32 Western blot of rat caudate lysate showing specific immunolabeling of the ~32k DARPP-32 phosphorylated at Thr75 (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: (-Ptase). The blot is identical to the control except that it was incubated in (-Ptase (1200 units for 30 min) before being exposed to the Anti-Thr75 DARPP-32. The immunolabeling is completely eliminated by treatment with (-Ptase.